NovaDigm Therapeutics has started a Phase Ib/IIa clinical trial of its NDV-3 vaccine, which is being developed to prevent episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC). Under the trial, which is a ...
Tags: NDV-3 Vaccine, NovaDigm